These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37180968)

  • 1. Impact of the Recognition Part of Dipeptidyl Nitroalkene Compounds on the Inhibition Mechanism of Cysteine Proteases Cruzain and Cathepsin L.
    Arafet K; Royo S; Schirmeister T; Barthels F; González FV; Moliner V
    ACS Catal; 2023 May; 13(9):6289-6300. PubMed ID: 37180968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling selectivity of chagasin mutants towards cysteine proteases cruzain or cathepsin L through molecular dynamics simulations.
    Toman NP; Kamenik AS; Santos LH; Hofer F; Liedl KR; Ferreira RS
    J Biomol Struct Dyn; 2021 Oct; 39(16):5940-5952. PubMed ID: 32715978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantum Mechanics/Molecular Mechanics Studies of the Mechanism of Cysteine Proteases Inhibition by Dipeptidyl Nitroalkenes.
    Arafet K; González FV; Moliner V
    Chemistry; 2020 Feb; 26(9):2002-2012. PubMed ID: 31692123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.
    Dos Santos AM; Cianni L; De Vita D; Rosini F; Leitão A; Laughton CA; Lameira J; Montanari CA
    Phys Chem Chem Phys; 2018 Sep; 20(37):24317-24328. PubMed ID: 30211406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental and Computational Study of Aryl-thiosemicarbazones Inhibiting Cruzain Reveals Reversible Inhibition and a Stepwise Mechanism.
    Martins LC; de Oliveira RB; Lameira J; Ferreira RS
    J Chem Inf Model; 2023 Mar; 63(5):1506-1520. PubMed ID: 36802548
    [No Abstract]   [Full Text] [Related]  

  • 6. Subsite specificity of trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids.
    Lecaille F; Authié E; Moreau T; Serveau C; Gauthier F; Lalmanach G
    Eur J Biochem; 2001 May; 268(9):2733-41. PubMed ID: 11322895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
    Silva JRA; Cianni L; Araujo D; Batista PHJ; de Vita D; Rosini F; Leitão A; Lameira J; Montanari CA
    J Chem Inf Model; 2020 Mar; 60(3):1666-1677. PubMed ID: 32126170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay.
    Wiggers HJ; Rocha JR; Fernandes WB; Sesti-Costa R; Carneiro ZA; Cheleski J; da Silva AB; Juliano L; Cezari MH; Silva JS; McKerrow JH; Montanari CA
    PLoS Negl Trop Dis; 2013; 7(8):e2370. PubMed ID: 23991231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
    Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
    Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1.
    Fonseca NC; da Cruz LF; da Silva Villela F; do Nascimento Pereira GA; de Siqueira-Neto JL; Kellar D; Suzuki BM; Ray D; de Souza TB; Alves RJ; Sales Júnior PA; Romanha AJ; Murta SM; McKerrow JH; Caffrey CR; de Oliveira RB; Ferreira RS
    Antimicrob Agents Chemother; 2015 May; 59(5):2666-77. PubMed ID: 25712353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting a novel allosteric mechanism of cruzain: A computer-aided approach.
    Hernández Alvarez L; Barreto Gomes DE; Hernández González JE; Pascutti PG
    PLoS One; 2019; 14(1):e0211227. PubMed ID: 30682119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and
    Boudreau PD; Miller BW; McCall LI; Almaliti J; Reher R; Hirata K; Le T; Siqueira-Neto JL; Hook V; Gerwick WH
    J Med Chem; 2019 Oct; 62(20):9026-9044. PubMed ID: 31539239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
    Cianni L; Sartori G; Rosini F; De Vita D; Pires G; Lopes BR; Leitão A; Burtoloso ACB; Montanari CA
    Bioorg Chem; 2018 Sep; 79():285-292. PubMed ID: 29783099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.
    Li L; Chenna BC; Yang KS; Cole TR; Goodall ZT; Giardini M; Moghadamchargari Z; Hernandez EA; Gomez J; Calvet CM; Bernatchez JA; Mellott DM; Zhu J; Rademacher A; Thomas D; Blankenship LR; Drelich A; Laganowsky A; Tseng CK; Liu WR; Wand AJ; Cruz-Reyes J; Siqueira-Neto JL; Meek TD
    J Med Chem; 2021 Aug; 64(15):11267-11287. PubMed ID: 34288674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
    Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J
    Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxydipeptidase activities of recombinant cysteine peptidases. Cruzain of Trypanosoma cruzi and CPB of Leishmania mexicana.
    Judice WA; Puzer L; Cotrin SS; Carmona AK; Coombs GH; Juliano L; Juliano MA
    Eur J Biochem; 2004 Mar; 271(5):1046-53. PubMed ID: 15009216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents.
    Zhu J; Li L; Drelich A; Chenna BC; Mellott DM; Taylor ZW; Tat V; Garcia CZ; Katzfuss A; Tseng CK; Meek TD
    Front Chem; 2022; 10():867928. PubMed ID: 35860632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl ureas represent a new class of anti-trypanosomal agents.
    Du X; Hansell E; Engel JC; Caffrey CR; Cohen FE; McKerrow JH
    Chem Biol; 2000 Sep; 7(9):733-42. PubMed ID: 10980453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiosemicarbazone derivatives: Evaluation as cruzipain inhibitors and molecular modeling study of complexes with cruzain.
    Jasinski G; Salas-Sarduy E; Vega D; Fabian L; Martini MF; Moglioni AG
    Bioorg Med Chem; 2022 May; 61():116708. PubMed ID: 35334448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new class of nonpeptidic inhibitors of cruzain.
    Brak K; Doyle PS; McKerrow JH; Ellman JA
    J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.